Biomaterial Database

Gynecomastia as a complication of auranofin therapy. 1988

H J Williams

Department of Internal medicine, University of Utah Medical Center, Salt Lake City, 84132.

Gynecomastia was found in a patient taking 12 mg of auranofin (AF) daily. The gynecomastia was noticed after AF was increased to this dose and resolved after the drug was discontinued. The patient refused rechallenge.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D006177	Gynecomastia	Enlargement of the BREAST in the males, caused by an excess of ESTROGENS. Physiological gynecomastia is normally observed in NEWBORNS; ADOLESCENT; and AGING males.	Adolescent Gynecomastia,Infant Gynecomastia,Male Breast Enlargement,Newborn Gynecomastia,Breast Enlargement, Male,Enlargement, Male Breast,Gynecomastia, Adolescent,Gynecomastia, Infant,Gynecomastia, Newborn
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D001172	Arthritis, Rheumatoid	A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	Rheumatoid Arthritis
D001310	Auranofin	An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.	Crisinor,Ridaura,Ridauran,SK&F D 39162,SK&F-39162,SK&F 39162,SK&F39162